A study that unexpectedly linked the heart drug Vytorin to excess cancer deaths has provoked controversy among heart specialists worried that the drug's risks may outweigh its benefits. The study, called SEAS, was designed to test whether Vytorin could prevent severe, age-related heart valve problems by sharply reducing cholesterol. But lead investigator Terje Pedersen of Ulleval University Hospital in Oslo reported Monday that the study turned up a "disturbing" link to cancer.



Go to Full Article